Skip to main content

Table 3 Immune-related adverse events

From: Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

Summary of immune-related adverse events
Immune-related adverse event Number of patients (%)
irAE 12 (52.2%)
Grade
 -G1/2 6 (26.1%)
 -G3/4 6 (26.1%)
irAE type
 -skin (rash) 3 (13.0%)
 -arthritis 3 (13.0%)
 -colitis 2 (8.7%)
 -encephalitis 2 (8.7%)
 -hypothyroidism 1 (4.3%)
 -pneumonitis 1 (4.3%)
 -neuropathy 1 (4.3%)